Do disease-modifying drugs (DMD) have a positive impact on the occurrence of secondary progressive multiple sclerosis? Yes.

Do disease-modifying drugs (DMD) have a positive impact on the occurrence of secondary progressive multiple sclerosis? Yes. Rev Neurol (Paris). 2020 Apr 04;: Authors: de Seze J, Bigaut K Abstract During the 20 past years, the management of multiple sclerosis (MS) has largely changed especially concerning therapeutical approach. Before 1996, treatments were restricted to corticosteroids for relapses, several symptomatic treatments and unselective immunosuppressive drugs (azathioprine, cyclophosphamide, methotrexate) with a low evidence of any efficacy. In the present review, we analyze the principal real-life cohorts of MS during several periods (before therapeutical modern area, first-generation treatment area and most recent period). Despite many methodological problems, we observe globally a delay of around 3-5 years between untreated cohorts and first-generation treatments for going to EDSS 6 which is probably the most robust score. This delay is clearly increase to at least 15 years with the most recent cohort treated first and second-line treatments confirming that early and more intensive treatment are necessary to have a long-term efficacy on disability progression and especially on severe disability represent by EDSS 6. Larger cohorts with longer follow-up is necessary to confirm these tendencies and OFSEP observatory or MS base will probably provide us the possibility to conclude in a couple of years. PMID: 32265072 [PubMed - as supplied by p...
Source: Revue Neurologique - Category: Neurology Tags: Rev Neurol (Paris) Source Type: research

Related Links:

Basel, 22 May 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will present new pooled pivotal satralizumab safety results for the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare, debilitating central nervous system disorder. These data are being presented at the 6th Annual Meeting of the European Academy of Neurology (EAN) and show satralizumab was well-tolerated in a broad patient population – including adolescents, for whom there is no approved medicine. Satralizumab is an investigational humanised monoclonal antibody that targets the interleukin-6 (IL-6) receptor, believed to play a key role in the i...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
AbstractMyelin oligodendrocyte glycoprotein antibody (MOG-Ab) is involved in the pathogenesis of central nervous system (CNS) demyelination disorders. We aimed to explore the spectrum of MOG-Ab-associated diseases in eastern India. A single-center, prospective observational study was done over a period of 2  years in a tertiary care hospital of eastern India. Patients with CNS demyelination disorders who tested positive for MOG-Ab using live cell-based assay were included in the study; while, those with age less than 1 year, documented preexisting CNS structural lesions, developmental delays or diagn osed multipl...
Source: Acta Neurologica Belgica - Category: Neurology Source Type: research
We present normally distributed variables using means and standard deviations and non-normally distributed variables using medians along with their ranges. Spearman's correlation coefficients were used to analyse correlations between the CSF's biomarker concentrations, and both unadjusted and Bonferroni adjusted p-values are reported. Orthogonal projection to latent structure discriminant analysis (OPLS-DA) was also used to find differences in terms of CSF metabolites between the relapsing and remitting patients [CIS, RR, PR versus PP, SP patients]. The OPLS-DA algorithm finds the projection direction, score vector, that g...
Source: Hellenic Journal of Nuclear Medicine - Category: Nuclear Medicine Tags: Hell J Nucl Med Source Type: research
ConclusionsNeurological involvement is seen about 5 years after the diagnosis of BD, and ocular involvement more commonly seen in these patients than non-NBD patients. More than half of the patients with acute onset parenchymal NBD had only one attack. No death was observed in the patients with non-parenchymal NBD. Biologic agents (Interferon-alpha and anti-TNF agents) were used in most patients.
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
Publication date: Available online 5 November 2019Source: Multiple Sclerosis and Related DisordersAuthor(s): Mustonen Tiina, Rauma Ilkka, Hartikainen Päivi, Krüger Johanna, Niiranen Marja, Selander Tuomas, Simula Sakari, Anne M. Remes, Kuusisto HannaAbstractBackgroundNatalizumab (NTZ) is widely used for highly active relapsing-remitting multiple sclerosis (MS). Inflammatory disease activity often returns after NTZ treatment discontinuation. We aimed to identify predictive factors for such reactivation in a real-life setting.MethodsWe conducted a retrospective survey in four Finnish hospitals. A computer-based sea...
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
ConclusionsAs demonstrated in other studies, OCS were generally effective. However, real-world effectiveness varied with other treatments. Relapse resolution of the first treatment with OCS was higher than with IVMP  ± OCS; similarly, relapse resolution was higher with RCI as the first treatment than with PMP/IVIG. Results demonstrate RCI’s effectiveness in appropriate patients. Limitations pertaining to claims-based research apply.FundingMallinckrodt Pharmaceuticals (Bedminster, NJ).
Source: Neurology and Therapy - Category: Neurology Source Type: research
This article provides an overview of the clinical and pathologic features of multiple sclerosis (MS) relapses and reviews evidence-based approaches to their treatment. RECENT FINDINGS Despite the increasing number and potency of MS treatments, relapses remain one of the more unpredictable and disconcerting disease aspects for many patients with MS, making their accurate recognition and treatment an essential component of good clinical care. The expanding range of relapse treatments now includes oral corticosteroids, comparable in efficacy to IV methylprednisolone at a fraction of the cost. While this development improve...
Source: CONTINUUM: Lifelong Learning in Neurology - Category: Neurology Tags: REVIEW ARTICLES Source Type: research
ConclusionsSince anti-MOG+ patients can have a multiphasic disease course and accumulate disability over time, high degree of suspicion and early diagnosis are of critical importance for treatment decision-making in clinical practice.AimThe aim of this case report is to enhance focus on an emerging disease spectrum among acquired CNS demyelinating disorders.
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
ConclusionMore data is needed to determine long-term disease modifying effects of corticosteroids. The findings of this study suggest that, perhaps, regular pulse glucocorticoid treatment may have important long-term consequences (beneficial) for patients with MS and it may achieve the NEDA target. Certainly, the magnitude of the reported effects deserves further investigation in both relapsing and progressive MS populations.
Source: Steroids - Category: Drugs & Pharmacology Source Type: research
Conclusion: Patients with isolated thalamic atrophy were at a higher risk for not reaching 2-year NEDA-3 and for EDSS increase than patients with no identified brain atrophy. The groups were clinically indistinguishable. A single measurement of thalamic and whole brain atrophy could help identify patients needing most effective therapies from early on. Introduction The quantification of brain atrophy by MRI has become an increasingly important part of evaluating neurodegeneration in MS (1, 2). Atrophy measures can reflect the damage on the central nervous system (CNS) caused by the pathological processes of the dis...
Source: Frontiers in Neurology - Category: Neurology Source Type: research
More News: Brain | Corticosteroid Therapy | Disability | Methotrexate | Multiple Sclerosis | Neurology